Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Oct 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Oct 2019 Planned End Date changed from 3 Mar 2020 to 22 Sep 2020.
- 02 Oct 2019 Planned primary completion date changed from 3 Mar 2020 to 22 Sep 2020.
- 09 Jul 2019 Status changed from recruiting to active, no longer recruiting.